Navigation Links
Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
Date:10/4/2011

DURHAM, N.C., Oct. 4, 2011 /PRNewswire/ -- Argos Therapeutics, Inc. today announced that its late scientific co-founder and scientific advisor Ralph M. Steinman, M.D., was awarded the Nobel Prize in medicine for the discovery of dendritic cells as critical sentinels of the immune system.

Dr. Steinman's discovery of dendritic cells and his research of dendritic cell biology and the role of dendritic cells in adaptive immunity have led to the development of Argos' core technology, Arcelis. 

"The Nobel Prize is further validation of the lifelong work of Dr. Steinman and Argos looks forward to continuing his work through further development of its dendritic cell-based immunotherapies," said Charles Nicolette, Ph.D., Argos' chief scientific officer and vice president of research and development. "We are planning to advance our Arcelis immunotherapy for the treatment of metastatic renal cell carcinoma, AGS-003, into a global Phase 3 clinical trial."

Dr. Nicolette added, "We extend our deepest condolences to Dr. Steinman's family for his untimely passing."

Dr. Steinman was a Henry G. Kunkel Professor at The Rockefeller University and a senior physician at The Rockefeller University Hospital. His research focused on the immune system including the human immune system in the setting of several diseases. His research aimed at developing vaccines and immune-based therapies for tumors, infections and autoimmune diseases.  Dr. Steinman received a B.S. degree from McGill University and an M.D. from Harvard University.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.  

Contact:
Jeff Abbey
Argos Therapeutics
(919) 287-6308
jabbey@argostherapeutics.com  


'/>"/>
SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
2. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
3. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
4. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
5. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
6. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
7. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
8. Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
9. Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
11. Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... Dec. 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... the discovery and development of innovative medicines targeting ... at its R&D day, held in ... is an anti-miR targeting microRNA-27 (miR-27) for the ... is an anti-miR targeting microRNA-17 (miR-17) for the ...
(Date:12/6/2016)... new study released today by the Alliance for Integrity ... Pricing Program will continue to expand at an unprecedented rate ... $23 billion in total purchases at the 340B price. This ... B drug reimbursement purchases over the next five years.      ... data on total drug purchases through 340B from 2005 to ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 2016 , ... When it came time to blow out his candles on his 14th birthday, ... Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family with a ... heart transplant recipient. , “He was playing at home, when we got the phone ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, ... coach who needs treatment for a brain tumor. , Jason Bauer and his ...
(Date:12/7/2016)... ... 07, 2016 , ... Augustine Insurance Agency, a locally owned ... owners in the greater Dallas metropolitan area, is announcing a charity event that ... Established in 2009 by active police professionals in the Dallas region, the Dallas ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to ... fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife ... children of the world. , In exchange for generous donations, customers will receive a ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... “Canine Filamentous Dermatitis Associated with Borrelia Infection” reveals that a condition ... in the prestigious Journal of Veterinary Science & Medical Diagnosis. , Morgellons disease ...
Breaking Medicine News(10 mins):